• About us
• Contact

Advertisement

Organisation › Details

Akribion Genomics (genome editing business of BRAIN Biotech AG until 6/23)

As a brand name of BRAIN Biotech AG, Akribion Genomics focuses on developing groundbreaking CRISPR nucleases into a new class of genetics-based cancer therapies and advanced genome editing tools, powered by the BRAIN Biotech Group BioIncubator. Akribion Genomics’ flexible CRISPR-based gene editing technology platform features distinct technology families (G-dases®) with broad application in Industrial Biotechnology and Agriculture, and offers a groundbreaking technological advantage for therapeutic and diagnostic solutions. Akribion Genomics is committed to using its technology with high ethical standards to improve products, processes and medical treatments. Its goal is to develop new treatment approaches in oncology by employing novel CRISPR technology that allows targeted cell depletion using RNA biomarkers. In addition, access to advanced CRISPR genome editing technology with freedom-to-operate will be made more feasible. Akribion Genomics is a spin-off in founding of BRAIN Biotech AG, a renowned international group of companies providing innovative biobased products and solutions to industry. For additional information, please visit www.akribion-genomics.com and LinkedIn. *

 

	Start	2022-10-01 splitoff (intern)
	End	2023-06-06 reorganised
	Group	BRAIN Biotech (Group)
	Today	Akribion Genomics AG (since 6/23)
	Predecessor	BRAIN Biotech AG
	Successor	Akribion Genomics AG (since 6/23)
	Industry	genome editing (gene editing)
	Industry 2	industrial biotechnology
	Person	Linnig, Lukas (BRAIN Biotech 202210– Business Head of Akribion Genomics before CFO of BRAIN AG joined 201704)
	Person 2	Krohn, Michael (BRAIN Biotech 202210– RnD Head of Akribion Genomics before RnD Head of BRAIN Biotech AG)
	Region	Zwingenberg
	Country	Germany
	City	64673 Zwingenberg
		Address record changed: 2023-10-12
Basic data	Employees	n. a.
		* Document for »About Section«: BRAIN Biotech AG. (9/28/23). "Press Release: BRAIN Biotech AG´s Akribion Genomics Team Wins First Prize in the “BioRiver Boost!” Startup Competition". Zwingenberg.
		Record changed: 2024-12-29

Advertisement

More documents for BRAIN Biotech (Group)

• [1] BRAIN Biotech AG. (9/20/24). "Press Release: BRAIN Biotech AG Concludes Major Pharma Compound Transaction Valued up to EUR 128.88 Million from Its BioIncubator". Zwingenberg....
• [2] BRAIN Biotech AG. (8/22/24). "Press Release: BRAIN Biotech AG Launches the Innovative Technology Platform MetXtra Enabling Unique Enzyme Solutions". Zwingenberg....
• [3] BRAIN Biotech AG. (5/29/24). "Press Release: BRAIN Biotech AG Announces the Appointment of Erik de Vries as Senior Business Development Director Enzymes". Zwingenberg & Greifswald....
• [4] BRAIN Biotech AG. (2/29/24). "Press Release: BRAIN Biotech AG Successfully Placed EUR 5.0 Million Convertible Bond for the Financing of Further Growth Initiatives [Not for US, AU, et al.]". Zwingenberg....
• [5] BRAIN Biotech AG. (9/14/23). "Press Release: BRAIN Biotech AG’s Akribion Genomics Technology Receives Patent Approval for Its Groundbreaking Nuclease G-dase E". Zwingenberg....
• [6] BRAIN Biotech AG. (2/8/23). "Press Release: Structural Proteins for the Development of Sustainable Materials. BRAIN Biotech and AMSilk Cooperate to Develop High-performance Bio-based Protein Fibers". Zwingenberg & Neuried....
• [7] BRAIN Biotech AG. (9/27/22). "Press Release: Change in the Executive Management Board of BRAIN Biotech AG, Genome Editing Activities Established Under the Akribion Genomics brand". Zwingenberg....
• [8] BRAIN Biotech AG. (5/30/22). "Press Release: Ongoing Dynamic Sales Development and Rising Profitability, 6M Reporting". Zwingenberg....
• [9] BRAIN Biotech AG. (5/30/22). "Press Release: Prof. Dr. Bernhard Hauer Leaves Supervisory Board of BRAIN Biotech AG for personal reasons". Zwingenberg....
• [10] Enzymicals AG. (3/8/22). "Press Release: Enzymicals AG Board of Supervisors Appoints New Management with Dr. Erik de Vries as CEO". Greifswald....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.